Comparative Pharmacology
Head-to-head clinical analysis: CLOTRIMAZOLE versus FULVICIN P G 330.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOTRIMAZOLE versus FULVICIN P G 330.
CLOTRIMAZOLE vs FULVICIN P/G 330
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol biosynthesis and increasing membrane permeability.
Fulvicin P/G 330 contains griseofulvin, which inhibits fungal cell mitosis by disrupting the microtubule function, binding to tubulin and preventing assembly of spindle fibers during metaphase.
Topical: Apply thin layer to affected area twice daily for 2-4 weeks. Oral troche: 10 mg troche dissolved slowly in mouth 5 times daily for 14 days. Vaginal: One 100 mg suppository intravaginally at bedtime for 7 days, or 200 mg suppository for 3 days, or 500 mg single dose.
330 mg orally once daily with fatty meal to enhance absorption.
None Documented
None Documented
Clinical Note
moderateClotrimazole + Tranilast
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Tranilast."
Clinical Note
moderateClotrimazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Tolfenamic acid."
Clinical Note
moderateClotrimazole + Nimesulide
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Nimesulide."
Clinical Note
moderateTerminal half-life is approximately 3-6 hours; due to rapid hepatic metabolism and extensive tissue distribution, clinical effects persist longer than plasma levels suggest.
Terminal half-life approximately 9-22 hours in adults, with a mean of ~13 hours. Clinical context: steady-state achieved in 2-3 days; may guide dosing interval.
Primarily fecal (biliary) as unchanged drug and metabolites; minimal renal excretion (<1% unchanged).
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites: ~36% in feces, ~13% in urine.
Category A/B
Category C
Antifungal
Antifungal
Clotrimazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Risedronic acid."